Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.

Ruoding TanCindy YunArpamas SeetasithDaniel SheinsonRobert WallsInnocent NgwaJosina C ReddyQing ZhangMatthew H SecrestPeter LambertKhaled Sarsour

Published in: The oncologist (2022)

This analysis adds to the clinical evidence base that use of ICIs before SARS-CoV-2 infection does not affect COVID-19 severity or survival outcomes, supporting the continued use of ICIs in cancer patients during the pandemic.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus